Kyverna Therapeutics, Inc., a leading biotechnology company focusing on autoimmune diseases, revealed its strategic priorities for the year 2025 and anticipated milestones in a recent press release on ...

Objectives SLE is a multifaceted autoimmune disorder with a complex pathogenesis involving genetic, environmental and ...

The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.

Caribou Biosciences has launched a Phase 1 trial testing its CAR T-cell therapy CB-010 for lupus affecting the kidneys and ...

HC Wainwright reiterated their buy rating on shares of Cabaletta Bio (NASDAQ:CABA – Free Report) in a report issued on Friday ...

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

Kyverna Therapeutics, Inc. (Kyverna, NASDAQ: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will present its ...

United States of America Background Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), associated with considerable morbidity and an increased risk of end-stage ...

Glomerulonephritis (GN), a severe kidney condition impacting glomeruli, can lead to complications like high blood pressure, ...

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent ...

"I am thrilled to represent Autoimmunity BioSolutions at the Sequire Investor Summit in Puerto Rico and to continue ...